Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials

• Egile Nagusiak: Neil J. Korman (Egilea), Richard B. Warren (Egilea), Jerry Bagel (Egilea), April W. Armstrong (Egilea), Melinda Gooderham (Egilea), Bruce Strober (Egilea), Diamant Thaçi (Egilea), Akimichi Morita (Egilea), Shinichi Imafuku (Egilea), Peter Foley (Egilea), Howard Sofen (Egilea), Min Zheng (Egilea), Lauren Hippeli (Egilea), Renata M. Kisa (Egilea), Subhashis Banerjee (Egilea), Andrew Blauvelt (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Aim: In the global phase 3 POETYK PSO-1 and PSO-2 trials, significantly greater proportions of deucravacitinib-treated patients met the coprimary endpoints (PASI 75, sPGA 0/1) at Week 16 versus placebo or apremilast-treated patients. This analysis evaluated onset of action and maintenance of respons...